SB
Samsara BioCapital Portfolio holdings
AUM
$489M
This Quarter Return
+138.41%
1 Year Return
+135.25%
3 Year Return
+909.96%
5 Year Return
+774.56%
10 Year Return
–
AUM
$729M
AUM Growth
+$729M
(+40%)
Cap. Flow
+$50M
Cap. Flow
% of AUM
6.87%
Top 10 Holdings %
Top 10 Hldgs %
81.82%
Holding
47
New
5
Increased
2
Reduced
8
Closed
4
Top Buys
| 1 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$63.4M |
| 2 |
UPB
Upstream Bio, Inc. Common Stock
UPB
|
$36.4M |
| 3 |
Neurogene
NGNE
|
$10.3M |
| 4 |
PVLA
Palvella Therapeutics, Inc. Common Stock
PVLA
|
$8.15M |
| 5 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
$7.09M |
Top Sells
| 1 |
Scholar Rock
SRRK
|
$50.8M |
| 2 |
Arcellx
ACLX
|
$7.67M |
| 3 |
LENZ
LENZ Therapeutics
LENZ
|
$6.39M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$4.53M |
| 5 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
$3.84M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$3.14B
| $243M | 33.3% | 5,612,896 -1,175,713 | -17% | -$50.8M |
|
|
CRGX
2
DELISTED
CARGO Therapeutics
CRGX
| $63.7M | 8.74% | 4,415,689 | – | – |
|
|
SEPN
3
Septerna, Inc. Common Stock
SEPN
$539M
| $63.4M | 8.7% | +2,768,520 | New | +$63.4M |
|
4
Mineralys Therapeutics
MLYS
$1.03B
| $62.5M | 8.57% | 5,074,916 | – | – |
|
|
5
Neurogene
NGNE
$264M
| $39.3M | 5.39% | 1,717,127 +449,337 | +35% | +$10.3M |
|
|
UPB
6
Upstream Bio, Inc. Common Stock
UPB
$923M
| $36.4M | 5% | +2,217,146 | New | +$36.4M |
|
|
LENZ
7
LENZ Therapeutics
LENZ
$1.1B
| $28.5M | 3.91% | 986,981 -221,492 | -18% | -$6.39M |
|
|
ALMS
8
Alumis Inc. Common Stock
ALMS
$479M
| $25.7M | 3.52% | 3,266,498 | – | – |
|
|
9
Arcellx
ACLX
$3.85B
| $19.5M | 2.67% | 253,641 -100,000 | -28% | -$7.67M |
|
10
Zymeworks
ZYME
$1.12B
| $14.6M | 2.01% | 1,000,000 | – | – |
|
11
Jasper Therapeutics
JSPR
$45.5M
| $12.5M | 1.72% | 584,642 | – | – |
|
|
AVDL
12
Avadel Pharmaceuticals
AVDL
$1.43B
| $10.2M | 1.4% | 967,527 | – | – |
|
13
Rhythm Pharmaceuticals
RYTM
$6.85B
| $9.66M | 1.33% | 172,647 | – | – |
|
14
Nkarta
NKTX
$151M
| $9.38M | 1.29% | 3,768,035 | – | – |
|
|
CTNM
15
Contineum Therapeutics
CTNM
$293M
| $8.63M | 1.18% | 588,816 | – | – |
|
|
PVLA
16
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $8.15M | 1.12% | +679,486 | New | +$8.15M |
|
|
SLRN
17
DELISTED
ACELYRIN
SLRN
| $7.92M | 1.09% | 2,523,022 | – | – |
|
|
OKUR
18
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$37.2M
| $7.09M | 0.97% | +824,155 | New | +$7.09M |
|
19
Leap Therapeutics
LPTX
$12M
| $7.02M | 0.96% | 2,442,352 | – | – |
|
|
ABVX
20
Abivax
ABVX
$6.12B
| $6.22M | 0.85% | 850,000 | – | – |
|
21
Aclaris Therapeutics
ACRS
$209M
| $5.91M | 0.81% | 2,385,060 +1,688,889 | +243% | +$4.19M |
|
22
Gossamer Bio
GOSS
$562M
| $5.55M | 0.76% | 6,130,268 | – | – |
|
|
CLYM
23
Climb Bio, Inc. Common Stock
CLYM
$151M
| $4.7M | 0.64% | 2,609,114 | – | – |
|
|
VRNA
24
Verona Pharma
VRNA
$9.16B
| $4.53M | 0.62% | 97,625 -97,600 | -50% | -$4.53M |
|
|
INZY
25
DELISTED
Inozyme Pharma
INZY
| $4.33M | 0.59% | 1,562,500 | – | – |
|